PT  - JOURNAL ARTICLE
AU  - Alligon, Mickaël
AU  - Mahlaoui, Nizar
AU  - Bouaziz, Olivier
TI  - Pitfalls in Time-to-Event Analysis of Registry Data: A Tutorial based on Simulated and Real Cases
AID  - 10.1101/2023.12.21.23300363
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.21.23300363
4099  - http://medrxiv.org/content/early/2023/12/24/2023.12.21.23300363.short
4100  - http://medrxiv.org/content/early/2023/12/24/2023.12.21.23300363.full
AB  - Survival analysis (also referred to as time-to-event analysis) is the study of the time elapsed from a starting date to some event of interest. In practice, these analyses can be challenging and, if methodological errors are to be avoided, require the application of appropriate techniques. By using simulations and real-life data based on the French national registry of patients with primary immunodeficiencies (CEREDIH), we sought to highlight the basic elements that need to be handled correctly when performing the initial steps in a survival analysis. We focused on right censoring, left truncation, competing risks, and recurrent events. Our simulations show that ignoring these aspects induces a bias in the results; we then explain how to analyze the data correctly in these situations. Rare disease registries are extremely valuable in medical research. We discuss the application of appropriate methods for the analysis of time-to-event from the CEREDIH registry. The objective of this tutorial article is to provide clinicians and healthcare professionals with better knowledge of the issues facing them when analyzing time-to-event data.Key messages boxWhen comparing naïve approaches and the proper methodology, we show that:Not considering right censoring leads to underestimation of survivalNot considering left truncation leads to overestimation of survivalTreating competing risks as right-censoring leads to overestimation of survivalAppropriate recurrent event methods allow to study all events for each patient and not only account for the first event.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere were no fundings for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data are not publicly availableCIDcombined immunodeficiencyCIFcumulative incidence functionCVIDcommon variable immunodeficiencyHSCThematopoietic stem cell transplantationMSMmultistate modelPIDprimary immunodeficiencySCIDsevere combined immunodeficiency